In December 2019, novel coronavirus (SARS-CoV-2) infected pneumonia MESHD occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of SARS-CoV-2 pneumonia MESHD compared to normal controls in Chinese Han population is limited. Our objective is to describe the clinical characteristics of SARS-CoV-2 pneumonia MESHD compared to normal controls in the Chinese Han population. In this case series of 752 patients, the full spectrum of cases is described. Fever MESHD was present in 86-90% of the patients. The second most common symptom was cough (49.1-51.0%), fatigue MESHD (25.2-27.1%), sputum (20.0-23.1%), and headache MESHD (9.8-11.1%). the mortality rate is 4.6% in Wuhan, 1.9% in Beijing, and 0.9% in Shanghai. Our findings showed that the levels of lymphocytes were 0.8(IQR, 0.6-1.1)109/L in Wuhan, 1.0(IQR, 0.7-1.4)109/L in Beijing, and 1.1 (IQR, 0.8-1.5) 109/L in Shanghai before admission to hospitals, respectively, indicating that cellular immune function might relate to the mortality. Based on the reference ranges of normal Chinese Han population and the data of the critically ill patients we have observed, it is recommended that reference ranges of people at high risk of COVID-19 MESHD infection are CD3+ lymphocytes below 900 cells/mm3, CD4 HGNC+ lymphocytes below 500 cells/mm3, and CD8 HGNC+ lymphocytes below 300 cells/mm3.

BACKGROUND: A recent outbreak of SARS-CoV-2 infection MESHD occurs mainly in China, with rapidly increasing the number of cases (namely COVID-19 MESHD). Abnormal liver functions MESHD are frequently present in these patients, here we aimed to clarify the clinical features of COVID-19 MESHD-related liver damage to provide some references for the clinical treatment. METHODS: In this retrospective, single-center study, we included all confirmed COVID-19 MESHD cases in Shanghai Public Health Clinical Center from January 20 to January 31, 2020. The outcomes were followed up until February 19, 2020. A total of 148 cases were analyzed for clinical features, laboratory parameters (including liver function tests), medications and the length of stay. FINDINGS: Of 148 confirmed SARS-CoV-2-infected MESHD patients, 49.3% were females and 50.7% were males. The median age was 50.5 years (interquartile range, 36-64). Patients had clinical manifestations of fever MESHD (70.1%), cough (45.3%), expectoration (26.7%) at admission. 75 patients (50.7%) showed abnormal liver functions at admission. Patients (n = 75) who had elevated liver function index were more likely to have a moderate-high degree fever MESHD (44% vs 27.4%; p = 0.035) and significantly present in male patients (62.67% vs 38.36%; p = 0.005). The numbers of CD4 HGNC+ and CD8 HGNC+ T cells were significantly lower in abnormal liver function group than those in normal liver function group. There was no statistical difference in prehospital medications between normal and abnormal liver function groups, while the utilization rate of lopinavir/ritonavir after admission was significantly higher in patients with emerging liver injury MESHD than that in patients with normal liver functions. Importantly, the emerging abnormal liver functions MESHD after admission caused a prolonged length of stay. INTERPRETATION: SARS-CoV-2 may cause the liver function damage MESHD and the Lopinavir/ritonavir should be applied carefully for the treatment of COVID-19 MESHD.